Skip to main content

Table 1 Baseline characteristics and homocysteine levels before and after treatment in stroke patients grouped according to treatment efficacy

From: A prospective cohort study of MTHFR C677T gene polymorphism and its influence on the therapeutic effect of homocysteine in stroke patients with hyperhomocysteinemia

  Poor efficacy group (n = 59) Effective efficacy group (n = 103) P value
Gender, male (%) 51 (86.4%) 87 (84.5%) 0.734
Age, years 46.51 ± 13.7 57.7 ± 13.3 < 0.001
Stroke types
 Hemorrhagic, n (%) 34 (57.6%) 45 (43.7%) 0.088
 Ischemic, n (%) 25 (42.4%) 58 (56.3%)
 Hypertension, n (%) 55 (93.2%) 84 (81.6%) 0.041
 Diabetes mellitus, n (%) 17 (28.8%) 38 (36.9%) 0.269
 Abnormal lipid metabolism, n (%) 34 (57.6%) 75 (72.8%) 0.070
 Hyperuricemia, n (%) 10 (16.9%) 7 (6.8%) 0.042
HCY, μmol/L
 Before treatment 26.49 ± 15.75 21.88 ± 18.99 0.116
 After treatment 21.64 ± 10.81 12.42 ± 5.99 < 0.001
MTHFR C677T genotype
 CC, n (%) 1 (1.7%) 9 (8.7%) < 0.001
 CT, n (%) 10 (16.9%) 45 (43.7%)  
 TT, n (%) 48 (81.4%) 49 (47.6%)